IONSIonis Pharmaceuticals, Inc.

1. Sep 23, 2026On September 23, 2026, Ionis and its partner, Roche, announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with IgAN. The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful …Regulation FD disclosure · Form 8-K
2. Sep 4, 2026On September 4, 2026, Ionis announced that its partner, Novartis, reported that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction …Regulation FD disclosure · Form 8-K
3. Sep 4, 2026On September 3, 2026, Ionis announced that the U.S. FDA has approved ZANVASTRO™ (zilganersen) for the treatment of AxD in pediatric and adult patients.Regulation FD disclosure · Form 8-K
4. Jul 29, 2026Ionis reports second quarter 2026 financial results and highlights progress on key programs.Earnings release · press release
5. Jul 9, 2026On July 9, 2026, Ionis announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with ATTR-CM did not meet the primary efficacy endpoint of the composite outcome of CV mortality and recurrent CV clinical events up to Week 140 compared with placebo.Regulation FD disclosure · Form 8-K
6. Jun 24, 2026On June 24, 2026, Ionis announced that the U.S. FDA has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with sHTG. TRYNGOLZA is available in a 50 mg or 80 mg dose and is self-administered once monthly via an autoinjector. sHTG is characterized …Regulation FD disclosure · Form 8-K
7. Jun 12, 2026On June 12, 2026, Ionis Pharmaceuticals, Inc. (“Ionis”) shared positive new data from the open-label extension study of CORE and CORE2 (“CORE-OLE”) evaluating olezarsen in people with severe hypertriglyceridemia (“sHTG”) during an oral presentation at the National Lipid Association Scientific Sessions in Chicago.Other event · Form 8-K
8. Jun 8, 2026Appointment of Ludwig N. Hantson to the Board of Directors On June 4, 2026, the Board of Directors (“Board”) of Ionis Pharmaceuticals, Inc. (the “Company”) appointed Ludwig N. Hantson as a member of the Company’s Board effective June 4, 2026, immediately following the Company’s 2026 Annual Meeting of Stockholders.Director or officer change · Form 8-K
9. May 28, 2026On May 28, 2026, Ionis announced that its partner, GSK, reported positive pivotal data for bepirovirsen, an investigational ASO for the treatment of CHB. Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published in the New England Journal of Medicine and presented at the European …Regulation FD disclosure · Form 8-K
10. Apr 29, 2026Ionis reports first quarter 2026 financial results and highlights progress on key programs.Earnings release · press release
11. Apr 21, 2026On April 21, 2026, we announced additional positive results from the pivotal study of zilganersen in children and adults living with AxD, a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments.Regulation FD disclosure · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.